US 12,433,899 B2
Therapeutics and method for treating osteoarthritis
Reid Grimes, Atlanta, GA (US); and David D. Waddell, Shreveport, LA (US)
Assigned to Calosyn Pharma Inc., Atlanta, GA (US)
Filed by Calosyn Pharma Inc., Atlanta, GA (US)
Filed on Dec. 27, 2024, as Appl. No. 19/002,866.
Application 19/002,866 is a continuation of application No. 18/681,818, previously published as PCT/US2022/039755, filed on Aug. 8, 2022.
Claims priority of provisional application 63/230,388, filed on Aug. 6, 2021.
Prior Publication US 2025/0120937 A1, Apr. 17, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/554 (2006.01); A61K 9/50 (2006.01); A61K 31/277 (2006.01); A61K 31/728 (2006.01); A61K 45/06 (2006.01); A61P 19/02 (2006.01)
CPC A61K 31/554 (2013.01) [A61K 9/50 (2013.01); A61K 9/5031 (2013.01); A61K 31/277 (2013.01); A61K 31/728 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01)] 17 Claims
 
1. A method for treating osteoarthritis in a patient in need thereof comprising: administering once to the patient an effective dose of a pharmaceutical composition comprising verapamil or a pharmaceutically acceptable salt thereof, wherein the verapamil is encapsulated in poly lactic/glycolic acid (PLGA) microspheres, and wherein the pharmaceutical composition is formulated for an initial burst between 0.01 ug to 5.00 ug of verapamil or a pharmaceutically acceptable salt thereof, followed by a lower concentration extended release of verapamil or a pharmaceutically acceptable salt thereof, between 0.05 ug and 25.00 ug a day, wherein between 85.0% and 95% of the microspheres are between 6.00 μm and 100.00 μm in diameter and further wherein the microspheres release verapamil for about one month after administration.